Cargando…
Phase II Trials in Drug Development and Adaptive Trial Design
Phase II clinical studies represent a critical point in determining drug costs, and phase II is a poor predictor of drug success: >30% of drugs entering phase II studies fail to progress, and >58% of drugs go on to fail in phase III. Adaptive clinical trial design has been proposed as a way to...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/ https://www.ncbi.nlm.nih.gov/pubmed/31312766 http://dx.doi.org/10.1016/j.jacbts.2019.02.005 |